Leading from Lived Experience
Ome Ogbru, PharmD
CEO & Founder
AINGENS
Leading from Lived Experience
Ome Ogbru, PharmD
CEO & Founder
AINGENS
In highly regulated industries, experience is rarely measured by years alone, but by how often leaders are forced to make decisions without perfect information, under pressure, and with real consequences attached. In life sciences, those moments arrive early and often, shaping not only judgment but also an enduring awareness of where systems strain, slow, or quietly fail the people working within them. Dr. Ogbru has spent more than two decades inside those systems, moving across academia, clinical practice, and senior medical affairs leadership roles at organizations such as Biogen, AstraZeneca, Baxter, and Bristol Myers Squibb. His work has placed him at the intersection of scientific rigor, regulatory complexity, and operational reality, leading global medical information teams and supporting major therapy launches across neuroscience, oncology, and rare diseases. Alongside this, his experience as a medical writer and consultant added another dimension, reinforcing the gap between how science is generated and how it is ultimately communicated. Those accumulated experiences now inform his perspective as Founder and CEO of AINGENS. TradeFlock spoke with Dr. Ogbru to examine how lived experience shapes leadership decisions in an era of accelerating change.
What experiences most shaped your journey to founding AINGENS?
Some experiences stay with you because they quietly change how you see your work. Creating a PharmD internship program at my alma mater, the University of the Pacific, was one such moment. Building something from scratch required designing a structure, aligning healthcare professionals around a shared vision, and demonstrating that students could add real value to patient care, which reshaped how I thought about contribution and ownership early in my career. That way of thinking carried forward into clinical practice and later into roles as a Medical Science Liaison and medical information leader, where the impact of credible scientific information became unmistakable. Seeing how evidence improves outcomes and how misinformation erodes trust revealed both the responsibility and the untapped potential within scientific teams. Over time, it became clear that talent was rarely the limitation, while systems and processes often were. AINGENS grew from that realization, built to help scientific expertise advance further, faster, and more efficiently.
What guiding principles shaped how you built AINGENS?
Working closely with scientific teams over many years leaves little room for theory about what helps and what hinders. I had seen too many tools promise transformation while quietly adding friction, which made it clear that usefulness had to come before sophistication. Building AINGENS and MACg meant committing to technology that supports teams without demanding their attention, allowing them to focus on meaningful scientific work. Respecting the realities of scientific content creation was equally important, since ideation, literature review, writing, citations, collaboration, and presentation are closely interconnected. Improving one step in isolation rarely changes outcomes, so the MACg platform had to support the full workflow while remaining reliable, secure, and flexible across teams. That perspective ultimately distilled into a simple belief that guided every decision: “The solution should work for the team, and solve real challenges.”
What legacy are you working toward through AINGENS?
Legacy becomes clearer when viewed through impact rather than visibility. AINGENS aims to set a meaningful benchmark for AI-driven scientific content generation while extending access beyond large institutions with extensive resources. Shaping how scientific information is created, interpreted, and shared is as important as the technology itself. Equally central is building a company that creates opportunities for those connected to it, whether team members, partners, or users who rely on these tools to unlock new possibilities. Early recognition and the launch of MACg represent the beginning of a longer journey, focused on contributing to a more efficient, productive, impactful, and technology-enabled future for scientific communication.
Which moments best reflect the impact you have created across your career?
Impact has rarely arrived as a single defining moment, but rather as a series of signals that the work was reaching beyond its original scope. As a pharmacy student, I wrote a review article on drug-resistant tuberculosis that was being distributed globally, which reinforced how rigorously science can influence care far from where it begins. Academic recognition followed through an award-winning publication, while clinical practice anchored those achievements in real patient outcomes and education. Industry roles expanded to influence further outcomes, particularly as a Medical Science Liaison, when evidence-based engagement contributed to formulary decisions and earned formal recognition. Over time, these experiences formed a consistent thread centered on translating science into decisions that matter. Launching AINGENS and our first solution, MACg, represents the most complete expression of that journey, bringing together academic experience, clinical practice insight, and operational leadership into a platform designed to scale impact across organizations.
How do you see AI reshaping scientific content and trust in the years ahead?
AI will change expectations not through novelty, but through results. As organizations move beyond experimentation, adoption will focus on measurable impact, shifting attention away from workforce reduction and toward enabling work that was previously limited by time and resources. Confidence in AI-supported scientific content will grow as teams see quality improve rather than diminish. At the same time, the stakes are rising. Misinformation and disinformation remain the most serious threats to scientific credibility, amplified by speed and scale. The same technologies that can spread misleading content can also reinforce trust when applied responsibly. Through MACg, AINGENS enables organizations to generate accurate, evidence-based scientific information efficiently, while future solutions will help identify misleading narratives and ensure credible insights reach the right audiences.
Featured Magazine -
All Magazines-
